Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GlycoTherapy

Financiado

Cerrado

New frontiers in advanced glycotherapy for cancer

Cancer remains a major cause of death despite phenomenal progress in current immunotherapy, that aims to boost host immune responses of antibodies and T cells, and their ability to distinguish cancer from normal cells. The three m... ver más

30/11/2027

TAU

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-13

ERC-2020-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TAU

2.15M€ | Lider

PERPLASTIC II

282.25K€ | Participante

Proyectos interesantes

SweetAim

Medical Technol...

Data Science

1M€ Cerrado

CAR-T-uning

Medical Technol...

Data Science

150K€ Cerrado

Allosteris

Medical Technol...

Data Science

2M€ Cerrado

ARGONAUT

Medical Technol...

Data Science

207K€ Cerrado

Tumor-Treg-Targeting

Medical Technol...

Data Science

1M€ Cerrado

SupraCODE

Medical Technol...

Data Science

Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 79 meses Fecha Inicio: 2021-04-13
Fecha Fin: 2027-11-30

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer remains a major cause of death despite phenomenal progress in current immunotherapy, that aims to boost host immune responses of antibodies and T cells, and their ability to distinguish cancer from normal cells. The three main cancer immunotherapies are therapeutic cancer vaccines, cellular therapeutics and immune checkpoint blockade, but those have only limited success mainly due to difficulties in identifying target antigens. Carbohydrate chains (glycans) ubiquitously occupy surface of cells, but on cancer they are aberrantly-expressed, in particular with a wide collection of sialic acid-glycans. Their antigenic complexity arise by sialic acid structure modification, linkages, length, protein/lipid scaffolds, surface organization and density. The presentation mode of glycans and their heterogeneity affect their immune recognition, but the fundamental knowledge of how these factors contribute to efficient cancer therapy in vivo has not been defined systematically. The primary objective of this proposal is to design a comprehensive novel cancer immunotherapy approach targeting glycan-neoantigens. We propose an innovative interdisciplinary approach that integrates glycobiology, immunology and nanotechnology, to design and fully investigate new frontiers in cancer ‘GlycoTherapy’ in vivo. Our discovery line is based on a two-arms modular platform to study both engineered carbohydrate-cancer vaccines and T cells, and their combined effects with checkpoint blockade on therapeutic glycan immune recognition in mouse models. Efficacy will be evaluated in detail by systematic characterization of immune cell and humoral responses with cutting-edge tools, including glycan microarrays, to track response repertoire and kinetics. Successful establishment and in-depth understanding of these therapies will provide a platform to devise and validate potent novel glyco-cancer diagnostic tools and therapeutics, and will instigate their prospective clinical translation in humans

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores